Please login to the form below

Not currently logged in
Email:
Password:

BMS and AZ gain approval for diabetes drug

The European Commission has granted marketing authorisation for Onglyza throughout the EU

The European Commission has granted marketing authorisation for the diabetes treatment Onglyza (saxagliptin) throughout the European Union(EU).

The once-daily 5 mg oral tablet dose is indicated in adult patients with type 2 diabetes mellitus in combination with other therapies (metformin, sulphonylurea, or thiazolidinedione) subject to certain criteria.

It was developed by Bristol-Myers Squibb(B-MS) and AstraZeneca(AZ) and is the first drug to be launched in Europe as part of the ongoing R&D collaboration between the two companies.

Béatrice Cazala, Bristol-Myers Squibb's president, Europe, and president, global commercialization, said: "The European Commission decision marks an important milestone in the alliance between Bristol-Myers Squibb and AstraZeneca."

Ulf Sather, AstraZeneca's regional vice president for Europe, commented: "Today's announcement is good news for those affected by type 2 diabetes and further demonstrates the commitment of AstraZeneca and Bristol-Myers Squibb to bring much needed options for the treatment of type 2 diabetes."

6th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics